Successful ceftazidime-avibactam treatment of MDR-KPC-positive Klebsiella pneumoniae infection in a patient with traumatic brain injury
Open Access
- 1 August 2017
- journal article
- case report
- Published by Ovid Technologies (Wolters Kluwer Health) in Medicine
- Vol. 96 (31), e7664
- https://doi.org/10.1097/md.0000000000007664
Abstract
Carbapenem-resistant Enterobacteriaceae infections are a serious health care problem, because of the high mortality. Carbapenem resistance is mainly caused by carbapenemases production, including Klebsiella pneumoniae carbapenemase (KPC). Ceftazidime-avibactam is a new cephalosporin/β-lactamase inhibitor combination for the treatment of complicated urinary, intra-abdominal infections, and nosocomial pneumonia caused by gram negative, or other serious gram-negative infections. We showed the case of a 27-year-old patient, hospitalized for traumatic brain injury and chest trauma, with KPC-producing Klebsiella pneumoniae infection. Blood and bronchial aspirate culture analysis detected an infection caused by MDR Klebsiella pneumoniae, resistant to meropenem, ertapenem, piperacillin/tazobactam, amoxicillin/clavulanic acid, aztreonam, ceftazidime, cefotaxime, cefepime, amikacin, ciprofloxacin, trimethoprim/sulfamethoxazole, colistin while it showed an intermediate sensitivity to gentamicin and was sensitive to ceftazidime-avibactam. Molecular analyses revealed that the isolate belonged to the epidemic clone sequence type 258 (ST258) carrying blaKPC-3, blaTEM-1, and blaSHV-11genes. After various combined antibiotic therapies without improvements, he was treated with ceftazidime-avibactam, on a compassionate-use basis. With ceftazidime-avibactam monotherapy clinical and microbiological clearance was obtained. A week after the end of the therapy microbiological analysis was repeated and a positive rectal swab for KPC-Klebsiella pneumoniae was found, becoming negative after 1 month. Moreover, the patient did not show any relapses for up to 18 weeks. This case indicates that ceftazidime-avibactam monotherapy could be efficacious against KPC positive Klebsiella pneumoniae infections.Keywords
This publication has 31 references indexed in Scilit:
- Combination treatment with extended-infusion ceftazidime/avibactam for a KPC-3-producing Klebsiella pneumoniae bacteraemia in a kidney and pancreas transplant patientInternational Journal of Antimicrobial Agents, 2016
- Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Bacteremia: Table 1.Clinical Infectious Diseases, 2016
- Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infectionsJournal of Antimicrobial Chemotherapy, 2016
- Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative OrganismsClinical Therapeutics, 2016
- Successful Treatment of Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae BacteremiaAntimicrobial Agents and Chemotherapy, 2015
- Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre studyJournal of Antimicrobial Chemotherapy, 2015
- Emergence of an extensively drug-resistant ArmA- and KPC-2-producing ST101 Klebsiella pneumoniae clone in ItalyJournal of Antimicrobial Chemotherapy, 2013
- Klebsiella pneumoniaecarbapenemase (KPC)-producingKlebsiella pneumoniae: a review of epidemiological and clinical aspectsExpert Opinion on Biological Therapy, 2012
- Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistanceFEMS Microbiology Reviews, 2011
- Prospective Observational Study of the Impact of VIM-1 Metallo-β-Lactamase on the Outcome of Patients with Klebsiella pneumoniae Bloodstream InfectionsAntimicrobial Agents and Chemotherapy, 2009